On November 25th, Kelun Hui announced that sichuan kelun pharmaceutical, a holding subsidiary of the company, has received approval for the clinical trial application of the innovative drug SKB501 developed by Kelun Botai. SKB501 is a novel ADC drug developed using the OptiDC™ platform technology with independent intellectual property rights, intended for the treatment of advanced solid tumors.
科伦药业：子公司SKB501新药临床试验申请获国家药品监督管理局批准
Sichuan Kelun Pharmaceutical: The clinical trial application for the new drug SKB501 by its subsidiary has been approved by the National Medical Products Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated